Inflammasome News and Research

RSS

Exercise counters inflammation that leads to diabetes, depression after COVID-19

While no medically recognized treatment exists for Long COVID, exercise may break the vicious cycle of inflammation that can lead to developing diabetes and depression months after a person recovers from the virus.

11 Mar 2022

Elevated P2X7 receptor levels in COVID-19 patients correlate with disease severity

In a recent study posted to the bioRxiv preprint server, researchers demonstrated that the soluble P2X7 receptor is increased in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients. They also showed that the elevated P2X7 receptors correlated with coronavirus disease 2019 (COVID-19) severity.

9 Mar 2022

Melatonin as a safe and potentially life-saving treatment for COVID-19

A new study discusses the possible role of melatonin, an antioxidant and anti-inflammatory agent, in treating COVID-19.

24 Feb 2022

SARS-CoV-2 viroporins mediate cytokine storm via mitochondrial permeability transition pore

Researchers demonstrated that the SARS-CoV-2 viroporins precipitate cytokine storm via the alteration of mitochondrial physiology in severe COVID-19.

24 Feb 2022

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

A new study discusses the state of current knowledge about the potential use of tea polyphenols in the prevention and treatment of COVID-19.

16 Feb 2022

Yale researchers confirm the health benefits of moderate calorie restrictions in humans

Decades of research has shown that limits on calorie intake by flies, worms, and mice can enhance life span in laboratory conditions. But whether such calorie restriction can do the same for humans remains unclear.

11 Feb 2022

Study explores inflammation of endothelial cells by exosomes from COVID-19 patients

In a new study, researchers revealed that the nucleotide-binding oligomerization domain-like receptors or NOD-like receptors family pyrin domain containing 3 (NLRP3) inflammasome is activated by the exosomes from plasma in COVID-19.

9 Feb 2022

Colchicine holds promise to reduce the risk of severe COVID-19

A recent article, published in Rheumatology and Therapy, reviews the potent evidence of colchicine against the SARS-CoV-2 infection.

7 Feb 2022

Investigating the immunology of COVID-19 infected children

Researchers published a new study that focused on the key principles of developmental immunology associated with immunobiology and the clinical impacts of COVID-19 infections in children and adults.

7 Feb 2022

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

A new article reviewed the innate immune detection and signaling pathways that the host uses against SARS-CoV-2.

7 Feb 2022

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

Researchers from China summarized the representative structures of SARS-CoV-2 proteins and discussed the development of novel therapeutic agents for targeting these proteins to treat and prevent COVID-19.

2 Feb 2022

Study shows SARS-CoV-2 prompts NLRP3 inflammasome activation through spike-ACE2 receptor interaction

New research assesses the NLR family pyrin domain containing 3 (NLRP3) inflammasome activation in response to SARS-CoV-2 and its spike protein, and the effects of this exposure in the presence of a-synuclein protein aggregate fibrils.

17 Jan 2022

First-responder cells launching the repair after heart attack promote inflammation overdrive

First-responder cells launching the repair after a heart attack are so frantic about fixing the damage that they promote more inflammation than necessary, new research in mice suggests.

5 Jan 2022

Impact of tumor environments on susceptibility and course of disease in those infected with SARS-CoV-2

A review assessed the impact of "hot" vs. "cold" immune/tumor environments (and associated therapies) on susceptibility and disease course in subjects with these two types of tumors and infected with SARS-CoV-2 to decipher the mechanisms that drive these adverse outcomes in COVID-19 infected cancer patients.

13 Dec 2021

Inflammasome News and Research

Exercise counters inflammation that leads to diabetes, depression after COVID-19

Elevated P2X7 receptor levels in COVID-19 patients correlate with disease severity

Melatonin as a safe and potentially life-saving treatment for COVID-19

SARS-CoV-2 viroporins mediate cytokine storm via mitochondrial permeability transition pore

Study suggests tea polyphenols may modulate COVID-19 via intestinal microbiota

Yale researchers confirm the health benefits of moderate calorie restrictions in humans

Study explores inflammation of endothelial cells by exosomes from COVID-19 patients

Colchicine holds promise to reduce the risk of severe COVID-19

Investigating the immunology of COVID-19 infected children

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

Representative structures of SARS-CoV-2 and development of therapeutic agents for targeting these proteins

Study shows SARS-CoV-2 prompts NLRP3 inflammasome activation through spike-ACE2 receptor interaction

First-responder cells launching the repair after heart attack promote inflammation overdrive

Impact of tumor environments on susceptibility and course of disease in those infected with SARS-CoV-2

UVA researchers uncover common link between lupus and macular degeneration

Study identifies ORF8 protein as a key COVID-19 causing factor

Role of interferon type I-driven responses associated with disease control in COVID-19

Preexisting rhinovirus infection and IFN induction in epithelium of asthma patients decreases SARS-CoV-2 infection

Two genetic risk variants in Black individuals may exacerbate sepsis and COVID-19 severity

Identification of common genes in COVID-19 and COPD

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®